Practice

Finnish Study Finds Anti-TNF Agents More Cost-Effective Than Rituximab in RA

July 25th 2019

By The Center for Biosimilars Staff

A patient-level simulation model using real-world data from Finland evaluated the cost-effectiveness of abatacept, tocilizumab, and anti–tumor necrosis factor (anti-TNF) therapies as compared with rituximab in patients with rheumatoid arthritis (RA) who received previous treatment with an anti-TNF agent.

The Top 5 Biosimilars Articles for the Week of July 15

July 19th 2019

The Center for Biosimilars® recaps the top stories for the week of July 15, 2019.

Recent Reports Explore Drug Survival, Cost Savings in Switches to Biosimilar Etanercept

July 18th 2019

By Kelly Davio

Patients with inflammatory diseases in the United States continue to wait for the availability of a biosimilar etanercept, despite the 2016 approval of Erelzi and the 2019 approval of Eticovo. However, in the European context, biosimilar etanercept is already available, and recently presented data demonstrate that, in some countries, use of the biosimilar is high and making an impact on healthcare costs.

More European Data Back the Use of Biosimilar CT-P13 in IBD

July 18th 2019

By Kelly Davio

The retrospective, observational, multicenter study included 141 patients, 96 with ulcerative colitis and 45 with Crohn disease, at 14 centers in Italy.

Multicenter European Study to Look at Real-World Experience of Patients Switched to Imraldi

July 18th 2019

By Allison Inserro

A hospital for rheumatological diseases in the United Kingdom is participating in an international study that is examining real-world evidence about patient experiences after they switch from reference adalimumab (Humira) to a biosimilar, Imraldi.

Using Value-Based RA Pathway Leads to a Shift to Biosimilars for AHG

July 17th 2019

By The Center for Biosimilars Staff

A variety of policy proposals have been put forward to help spur the US uptake of biosimilars, from legislative solutions to regulatory changes, but some providers are taking the matter into their own hands with concerted efforts to bring biosimilars to the clinic.

In Eastern Europe, CT-P13 Provides Effective, Cost-Saving Alternative to Reference Infliximab in IBD

July 15th 2019

By Kelly Davio

Access to biologic drugs is uneven, even in nations with relatively robust healthcare resources. In lower-resource areas, such as Eastern Europe, access to biologic therapy for diseases like inflammatory bowel disease (IBD) may be very limited.

In a Single-Center Study, Patients With AS Remained in Remission After a Switch to CT-P13

July 14th 2019

By The Center for Biosimilars Staff

As more health systems seek to make use of the cost savings associated with biosimilars, data continue to accrue to support switching patients to these products. One recent paper, published in The Journal of Clinical Medicine, reported that, after a switch from reference infliximab to biosimilar CT-P13 (Inflectra, Remsima), patients with ankylosing spondylitis (AS) who switched to the biosimilar remained in remission at 18 months post-switch.

Study Finds Characteristics Likely to Predict Conversion to AMD in Second Eye in Patients Treated With Anti-VEGFs

July 11th 2019

By Allison Inserro

A secondary post hoc analysis of patients who had neovascular age-related macular degeneration (AMD) and were treated with intravitreal aflibercept or ranibizumab—2 widely used anti-vascular endothelial growth factor (anti-VEGF) therapies—found that those with certain characteristics had a substantial risk of conversion to AMD in the untreated eye.

Research Finds "Significant Association" Between Pharma Payments to Prescribers and Biologic Spending in Medicare

July 10th 2019

By Kelly Davio

This week, a research letter appearing JAMA Internal Medicine reported on efforts to understand whether there exists an association between payments from drug makers and Medicare spending on adalimumab and certolizumab.